---
document_datetime: 2025-12-04 12:00:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/dengvaxia-epar-all-authorised-presentations_en.pdf
document_name: dengvaxia-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.3797152
conversion_datetime: 2025-12-28 09:18:56.703491
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Content (concentration) Pack size

EU/1/18/1338/001

EU/1/18/1338/002

EU/1/18/1338/003

EU/1/18/1338/004

EU/1/18/1338/005

Dengvaxia

Dengvaxia

Dengvaxia

Dengvaxia

Dengvaxia

--¹

--¹

--¹

--¹

--¹

Powder and solvent for suspension for

injection

Powder and solvent for suspension for

injection

Powder and solvent for suspension for

injection

Powder and solvent for suspension for

injection

Powder and solvent for suspension for

injection

Subcutaneous use

Subcutaneous use

Subcutaneous use

Subcutaneous use

Subcutaneous use powder: vial

(glass); solvent:

pre-filled syringe

(glass)

powder: vial

(glass); solvent:

pre-filled syringe

(glass)

powder: vial

(glass); solvent:

pre-filled syringe

(glass)

powder: vial

(glass); solvent:

pre-filled syringe

(glass)

powder: vial

(glass); solvent:

vial (glass)

Powder: 1 dose;

solvent: 0.5 ml

Powder: 1 dose;

solvent: 0.5 ml

Powder: 1 dose;

solvent: 0.5 ml

Powder: 1 dose;

solvent: 0.5 ml

Powder: 5 doses;

solvent: 2.5 ml

1 vial + 1 pre-filled syringe + 2 needles

10 vials + 10

pre-filled syringes +

20 needles

1 vial + 1 pre-filled syringe

10 vials + 10

pre-filled syringes

5 sets of 2 vials (1

with powder + 1

with solvent, 5

doses each)

--¹ After reconstitution, one dose (0.5 mL) contains: Chimeric yellow fever dengue virus serotype 1* (live, attenuated).............................................4.5 - 6.0 log10 CCID50/dose** Chimeric yellow fever dengue virus serotype 2* (live, attenuated).............................................4.5 - 6.0 log10 CCID50/dose** Chimeric yellow fever dengue virus serotype 3* (live, attenuated).............................................4.5 - 6.0 log10 CCID50/dose** Chimeric yellow fever dengue virus serotype 4* (live, attenuated).............................................4.5 - 6.0 log10 CCID50/dose** * Produced in Vero cells by recombinant DNA technology. This product contains genetically modified organisms (GMOs). ** CCID50: 50% Cell Culture Infectious Dose. Medicinal product no longer authorised